Pancreatic ductal adenocarcinoma concomitant with pancreatic metastases of clear-cell renal cell carcinoma: a case report

Haeberle, Lena; Busch, Mirjam; Kirchner, Julian; Fluegen, Georg; Antoch, Gerald; Knoefel, Wolfram Trudo; Espósito, Irene

doi:10.1186/s13256-021-02768-8

Cited by 4 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surgical indications in PCL are limited to evidence of malignancy or risk of malignancy on preoperative tests, or, in particular cases, the impossibility of excluding malignancy after an equivocal cyst workup, following the decision of a multidisciplinary board. In these latter cases, a molecular analysis of cyst fluid can support the surgical decision [42,43]. According to European guidelines, surgery for IPMN is firmly recommended if there is evidence of malignancy or HGD, the presence of a solid mass, tumor-related jaundice, enhanced mural nodule ≥ 5 mm or dilatation of MPD ≥ 10 mm.…”

Section: Initial Indication For Surgery and The Results Of The Resect...mentioning

confidence: 99%

Novel Insights into Postoperative Surveillance in Resected Pancreatic Cystic Neoplasms—A Review

Balaban,

Coman,

Balaban

et al. 2024

Diagnostics

View full text Add to dashboard Cite

Pancreatic cystic lesions (PCL) are frequently encountered in clinical practice and some are referred to surgery due to their neoplastic risk or malignant transformation. The management of PCL involves complex decision-making, with postoperative surveillance being a key component for long-term outcomes, due to the potential for recurrence and postoperative morbidity. Unfortunately, the follow-up of resected patients is far from being optimal and there is a lack of consensus on recommendations with regard to timing and methods of surveillance. Here, we summarize the current knowledge on the postoperative surveillance of neoplastic pancreatic cysts, focusing on the mechanisms and risk factors for recurrence, the recurrence rates according to the initial indication for surgery, the final result of the surgical specimen and neoplastic risk in the remaining pancreas, as well as the postsurgical morbidity comprising pancreatic exocrine insufficiency, metabolic dysfunction and diabetes after resection, according to the type of surgery performed. We analyze postsurgical recurrence rates and morbidity profiles, as influenced by different surgical techniques, to better delineate at-risk patients, and highlight the need for tailored surveillance strategies adapted to preoperative and operative factors with an impact on outcomes.

show abstract

Section: Initial Indication For Surgery and The Results Of The Resect...mentioning

confidence: 99%

Novel Insights into Postoperative Surveillance in Resected Pancreatic Cystic Neoplasms—A Review

Balaban,

Coman,

Balaban

et al. 2024

Diagnostics

View full text Add to dashboard Cite

show abstract

“…A major stake in the differential diagnosis is with PDAC. While differential diagnosis with PDAC seems straightforward—with one being hypovascular and the other being hypervascular—synchronous PM from RCC and PDAC have been reported in the literature [ 75 ]. Synchronous RCC and PDAC have also been described in case reports [ 76 ].…”

Section: Discussionmentioning

confidence: 99%

Metastatic Renal Cell Carcinoma to Pancreas: Case Series and Review of the Literature

et al. 2023

View full text Add to dashboard Cite

Metastasis to the pancreas represents a small proportion of all pancreatic malignancies. Among primary tumors that metastasize to the pancreas, renal cell carcinoma (RCC) is one of the most common causes of metastatic pancreatic lesions. We herein report a case series of three patients with pancreatic metastasis from RCC. The first is a 54-year-old male with a history of left nephrectomy for RCC, in whom an isthmic pancreatic mass suggestive of a neuroendocrine lesion was found during oncological follow-up. Endoscopic ultrasound (EUS)-guided fine needle biopsy (FNB) identified pancreatic metastasis of RCC and the patient was referred for surgery. The second case is a 61-year-old male, hypertensive, diabetic, with left nephrectomy for RCC six years previously, who complained of weight loss and was found with a hyperenhancing mass in the head of the pancreas and a lesion with a similar pattern in the gallbladder. EUS-FNB from the pancreas proved to be a metastatic pancreatic lesion. Cholecystectomy and treatment with tyrosine kinase inhibitors were recommended. The third case is a 68-year-old dialysis patient referred for evaluation of a pancreatic mass, also confirmed by EUS-FNB, who was started on sunitinib treatment. We report a literature summary on epidemiology and clinical features, diagnosis and differential diagnosis and treatment and outcomes in pancreatic metastasis of RCC.

show abstract

“…Numerous studies have so far dealt with this disease, partly in the form of case studies, or in the form of institutional experience reports, of which 1470 observations were reported by 2022 [1], to which 259 isPMRCC have since been added [2,3,[45][46][47][48][49][50][51][52][53][54][55][56], bringing the total number to 1729.…”

Section: Introductionmentioning

confidence: 99%

Genetic and Epigenetic Characteristics in Isolated Pancreatic Metastases of Clear-Cell Renal Cell Carcinoma

Sellner,

Compérat,

Klimpfinger

2023

IJMS

View full text Add to dashboard Cite

Isolated pancreatic metastases of renal cell carcinoma (IsPMRCC) are a rare manifestation of metastatic, clear-cell renal cell carcinoma (RCC) in which distant metastases occur exclusively in the pancreas. In addition to the main symptom of the isolated occurrence of pancreatic metastases, the entity surprises with additional clinical peculiarities: (a) the unusually long interval of about 9 years between the primary RCC and the onset of pancreatic metastases; (b) multiple pancreatic metastases occurring in 36% of cases; (c) favourable treatment outcomes with a 75% 5-year survival rate; and (d) volume and growth-rate dependent risk factors generally accepted to be relevant for overall survival in metastatic surgery are insignificant in isPMRCC. The genetic and epigenetic causes of exclusive pancreatic involvement have not yet been investigated and are currently unknown. Conversely, according to the few available data in the literature, the following genetic and epigenetic peculiarities can already be identified as the cause of the protracted course: 1. high genetic stability of the tumour cell clones in both the primary tumour and the pancreatic metastases; 2. a low frequency of copy number variants associated with aggressiveness, such as 9p, 14q and 4q loss; 3. in the chromatin-modifying genes, a decreased rate of PAB1 (3%) and an increased rate of PBRM1 (77%) defects are seen, a profile associated with a favourable course; 4. an increased incidence of KDM5C mutations, which, in common with increased PBRM1 alterations, is also associated with a favourable outcome; and 5. angiogenetic biomarkers are increased in tumour tissue, while inflammatory biomarkers are decreased, which explains the good response to TKI therapy and lack of sensitivity to IT.

show abstract

Pancreatic ductal adenocarcinoma concomitant with pancreatic metastases of clear-cell renal cell carcinoma: a case report

Cited by 4 publications

References 14 publications

Novel Insights into Postoperative Surveillance in Resected Pancreatic Cystic Neoplasms—A Review

Novel Insights into Postoperative Surveillance in Resected Pancreatic Cystic Neoplasms—A Review

Metastatic Renal Cell Carcinoma to Pancreas: Case Series and Review of the Literature

Genetic and Epigenetic Characteristics in Isolated Pancreatic Metastases of Clear-Cell Renal Cell Carcinoma

Contact Info

Product

Resources

About